FAM24B: A Potential Drug Target and Biomarker (G196792)

Target Name: FAM24B

NCBI ID: G196792

FAM24B

FAM24B: A Potential Drug Target and Biomarker

FAM24B, also known as filename-associated module 24B, is a protein that is expressed in various tissues and cells in the body. Its function is not well understood, but it is known to be involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. FAM24B has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, FAM24B has emerged as a promising drug target and biomarker for a variety of diseases.

The discovery and characterization of FAM24B

FAM24B was first identified in the 1990s as a gene that was expressed in a variety of tissues and cells, including brain, heart, liver, and pancreas. The gene was named based on its location in the chromosome, file-associated module 24B. Since then, numerous studies have demonstrated that FAM24B plays a role in the regulation of cellular processes, including cell adhesion, migration, and invasion.

One of the most significant findings related to FAM24B is its role in cell adhesion. FAM24B is known to be involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues. Studies have shown that FAM24B is essential for the formation of tight junctions in various tissues, including the brain and the placenta. This suggests that FAM24B may be a useful target for drugs that are designed to modulate cell adhesion.

FAM24B is also involved in the regulation of cell migration and invasion. Studies have shown that FAM24B plays a role in the migration of various cell types, including cancer cells. This suggests that FAM24B may be a useful target for drugs that are designed to inhibit cell migration and invasion.

The role of FAM24B in disease development

FAM24B has also been shown to play a role in the development and progression of various diseases. For example, studies have shown that high levels of FAM24B are associated with the development of certain types of cancer, including breast and ovarian cancer. This suggests that FAM24B may be a useful biomarker for cancer, and that targeting FAM24B may be a promising strategy for the development of new cancer therapies.

In addition to its role in cancer development, FAM24B has also been shown to be involved in the development of other diseases. For example, studies have shown that FAM24B is involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. This suggests that FAM24B may be a useful target for drugs that are designed to treat neurodegenerative diseases.

FAM24B as a drug target

Based on its involvement in cellular processes such as cell adhesion, migration, and invasion, as well as its role in the development and progression of various diseases, FAM24B has emerged as a promising drug target. Studies have shown that FAM24B can be targeted with small molecules, antibodies, and other therapeutic agents. For example, studies have shown that FAM24B is responsive to inhibitors of the protein tyrosine phosphatase (PTP), a enzyme that is involved in the regulation of cellular processes.

In addition to its responsiveness to PTP inhibitors, FAM24B is also known to be responsive to inhibitors of the protein kinase C (PKC), a enzyme that is involved in the regulation of cellular processes such as cell adhesion and migration. This suggests that FAM24B may be a

Protein Name: Family With Sequence Similarity 24 Member B

The "FAM24B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM24B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets